HexemBio unveils three-generation pipeline after raising $15.5 million

HexemBio said it has built a three-generation product line on its synthetic biology platform and secured $15.5 million in total funding, including new investors alongside Draper Associates and Boost VC. The company is aiming for first-in-human trials of its lead blood stem cell therapy in 2027 as it expands into an injectable and a skin product.

Why it matters: - HexemBio is trying to turn a regenerative science platform into multiple products, which could broaden its commercial reach beyond a single therapy. - The lead program is aimed at improving bone marrow transplants for patients with blood disease, a setting where better stem cell function could affect treatment outcomes. - The company’s pipeline also points to a move from transplant medicine into broader longevity and skin-care applications.

What happened: - HexemBio announced a three-generation product line built on its synthetic biology platform. - The company said it has raised $15.5 million in total funding. - Three new investors joined existing backers Draper Associates and Boost VC. - Happiness Capital is among the new investors. - The announcement came Sept. 15, 2026, from San Francisco.

The details: - HexemBio’s first-generation lead program is a cell therapy that aims to rejuvenate a patient’s own blood stem cells rather than replace or reprogram them. - The company’s Synthetic Human Yolk Sac recreates the developmental environment where the body’s first blood stem cells arise. - In the process, a patient’s aged cells are briefly returned to that environment outside the body and then infused back. - The platform was published in Nature, and additional manuscripts are under review. - HexemBio has filed 17 patent applications worldwide, and two have been granted. - The first-generation program received Orphan Drug Designation in July 2025. - HexemBio completed its Pre-IND meeting in January 2026. - The company is targeting first-in-human trials in 2027. - The second-generation product is an injectable that carries defined signals from the same developmental environment without requiring cells to be collected. - HexemBio is developing the injectable for patients who could benefit from restored stem cell function outside the transplant setting. - The second-generation program is in advanced preclinical development. - A third-generation product designed to enhance and protect skin is in its final phase of development. - HexemBio said the skin product comes with an aggressive go-to-market strategy. - HexemBio was founded in 2024 and operates from Berkeley and New York City. - The company describes itself as a longevity and AI discovery company focused on regenerative therapies for aging blood stem cells. - The company says machine learning helped identify a defined molecular recipe that rejuvenates aged hematopoietic stem cells. - The company received FDA Orphan Drug Designation in July 2025 and completed its FDA Pre-IND meeting in January 2026. - More information is available in HexemBio’s announcement.

Between the lines: - The funding update suggests investor confidence is extending beyond a single lead asset and into a platform with multiple commercial paths. - The jump from transplant-focused therapy to an injectable and then skin protection shows HexemBio is trying to build a broader product stack from one core science base. - Tim Draper said the team’s breakthrough technology has expanded into three new product categories, with more potentially to come.

What's next: - HexemBio’s main near-term goal is to move its lead transplant program into human clinical trials in 2027. - The company is advancing its second-generation injectable through preclinical work. - HexemBio is also pushing its skin product toward launch. - Further development and possible new product categories may follow if the platform continues to work as expected.

The bottom line: - HexemBio is betting that one stem-cell rejuvenation platform can support a pipeline spanning transplants, injectables and skin care.